Razan Abdelmoula Musa Ali¹, Sara Elsayed Hussein Elsayed¹, Tasneem Osman Eissa Elnaeem¹, Leena Ahmed khairy Haroun¹, Afraa yousof abdalkareem alameen¹, Mugtaba Ahmed Abdalrahman Ahmed², Hussein Elsayed², Mohammed Altyb Alshykh Aboshanab², Mohammed Alfatih², Mohamed Abdulkarim²

¹MBBS Khartoum university faculty of Medical laboratory, Khartoum, Sudan
²MBBS Alzaiem Alazhari university faculty of medicine, Khartoum, Sudan

*Corresponding Author: Mohammed Altyb Alshykh Aboshanab, Faculty of Medicine, Alzaiem Alazhari University, Sudan.

Received: August 31, 2021; Published: September 25, 2021

Abstract

Introduction: Tuberculosis infection is a very serious pulmonary infection, sometimes is co-exist with another infectious disease such as Hepatitis B and C which are very dangerous liver infection and may lead to liver cirrhosis and hepatocellular carcinoma.

Methods: This is a descriptive cross- sectional study. It was conducted at Abu Anja hospital which is one of the biggest hospitals in Khartoum state during a period from February-April 2016.

Result: A total serum specimen of 160 samples was taken from patients with Tuberculosis infection. Aged between 10-80 years (118 males 42 female) were collected. 11 cases (6.9%) were found to be seropositive for Hepatitis B Virus infection). 4 cases (2.5%) were found to be seropositive for Hepatitis C Virus infection. The highest frequency of Hepatitis B Virus seropositivity among age group was observed in the age group 21-40 years. Hepatitis C Virus was found to be highest in the age group 21-40 years also.

Conclusion: Co-infection with viral hepatitis (HBV, HCV) among TB patient increases the risk of hepatotoxicity occurring during the treatment of tuberculosis, therefore, it is important to know the seroprevalence of HBV and HCV among TB patients before starting the treatment. Furthermore, once the patient started the treatment of TB, there must be regular follow up for monitoring the indications of hepatotoxicity and routine evaluation of liver function test must be considered wherever possible.

Keywords: Prevalence; Tuberculosis; Hepatitis C and B

References

1. World Health Organization. “Global tuberculosis report” (2020).
2. Wong WM., et al. “Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection”. Hepatology1 (2000): 201-206.
3. Saukkonen JJ., et al. “Hepatotoxicity of Antituberculosis Therapy Subcommittee”.
4. Jussi J Saukkonen., et al. “An official ATS statement: hepatotoxicity of antituberculosis therapy”. American Journal of Respiratory and Critical Care Medicine8 (2006): 935-952.
5. Nail AM., et al. “Seroprevalence of hepatitis B and C viruses among tuberculosis patients”. Sudan Journal of Medical science 8 (2013): 17-22.
6. Abdallah TM., et al. “Sero-Prevalence of Hepatitis B and Hepatitis C Viruses among Tuberculosis Patients in Kassala, Eastern Sudan”. Global Journal of Infectious Diseases and Clinical Research 1 (2015): 001-003.
7. Sirinak C., et al. “Viral hepatitis and HIV – associated tuberculosis: Risk factors and TB treatment outcomes in Thailand”. BMC Public Health 8 (2008): 245.
8. Kuniholm MH., et al. “Risk factors and algorithms to identify hepatitis C, hepatitis B,and HIV among Georgian tuberculosis patients”. International Journal of Infectious Diseases 12 (2008): 51-56.
9. Akhtar I., et al. “Sero-prevalence of HBV and HCV at tuberculous patients at Sheikh Zayed Hospital Rahim Yar Khan, Pakistan”. Biomedica 29 (2013): 69-72.
10. Maheshwari N., et al. “Hepatitis B virus carrier rate in pulmonarytuberculosis patients”. 36.1 (1989): 39-40.
11. Tandon BN., et al. “Epidemiology of hepatitis B virus infection in India”. Gut 38 (1996): S56-S59.
12. Mudawi HM., et al. “Prevalence of hepatitis B virus infection in the Gezira state of central Sudan”. Saudi Journal of Gastroenterology 13 (2007): 81-83.
13. Abdlah TM., et al. “Seroprevalence and epidemiological factors of hepatitis B virus (HBV) infection in Eastern Sudan”. International Journal of Medicine and Medical Sciences 3 (2011): 239-241.
14. Tajeldin M., et al. “Seroprevalence and epidemiological factors of hepatitis B virus (HBV) infection in Eastern Sudan”. International Journal of Medicine and Medical Sciences7 (2011): 239-241.
15. Marwan M., et al. “A Diagnostic Laboratory-Based Study on Frequency and Distribution of Viral Hepatitis B and C Among Sudanese”. Open Virology Journal 11 (2017): 98-107.
16. Badawi MM., et al. “Systematic review and meta-analysis of HIV, HBV and HCV infection prevalence in Sudan”. Virology Journal 148 (2018).
17. Karima Chaabna. “Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis”. PLoS One2 (2016): e0149966.
18. Blal CA., et al. “High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil”. European Journal of Clinical Microbiology and Infectious Diseases 24 (2005): 41-43.
19. Aires RS., et al. “Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil”. Journal of Clinical Virology 54 (2012): 327-331.
20. Mudawi HMY. “Epidemiology of viral hepatitis in Sudan”. Clinical and Experimental Gastroenterology 1 (2008): 9-13.
21. Reis NR., et al. “Hepatitis C virus infection in patients with tuberculosis in Central Brazil”. International Journal of Tuberculosis and Lung Disease 15: 1397-402.
22. Richards D., et al. “High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia”. International Journal of Tuberculosis and Lung Disease 10 (2006): 396-412.
23. Agha MA., et al. “Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity”. Egyptian Journal of Chest Diseases and Tuberculosis 64 (2015): 91-96.
24. Khalili H., et al. “Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome”. Journal of Pharmaceutical Sciences 17 (2009): 163-167.
25. Hussain N., et al. “Sensitivity Comparison between Rapid Immuno-Chromatographic Device Test and ELISA in Detection and Sero-Prevalence of HBsAg and Anti-HCV antibodies in Apparently Healthy Blood Donors of Lahore, Pakistan”. World Academy of Science, Engineering and Technology 60 (2011): 1112-1114.
26. Khan JK. “Evaluation of the Performance of Two Rapid Immunochromatographic Tests for Detection of Hepatitis B Surface Antigen and Anti HCV Antibodies Using Elisa Tested Samples”. Special Edition Annals 1 (2010).
27. Mubashir Nazir. “A Comparative Study of Screening of Hepatitis B by Two Different Immunochromatographic Methods among Patients Attending a Tertiary Care Hospital”. International Journal of Current Microbiology and Applied Sciences (IJCMAS) (2020).

Citation

Citation: Mohammed Altyb Alshykh Aboshanab., et al. “Prevalence of Hepatitis B and Hepatitis C Co-infection with Tuberculosis Patients in Khartoum State Sudan”. Acta Scientific Women's Health 3.10 (2021): 42-47.

Copyright

Copyright: © 2021 Mohammed Altyb Alshykh Aboshanab., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.